Last reviewed · How we verify

NCT03417206: FESSPRD

PRD-guided Analgesia During FESS for Intraoperative Blood Loss

Status unknown NA Last updated 22 October 2020
What this trial tests

NA trial testing Remifentanil in Endoscopic Sinus Surgery in 120 participants. Status unknown.

Timeline
1 September 2021
Primary endpoint
15 January 2023
15 January 2023

Quick facts

Lead sponsorMedical University of Silesia
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment120
Start date1 September 2021
Primary completion15 January 2023
Estimated completion15 January 2023

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Silesia

Who can join

Adults 18 to 80, any sex, with Endoscopic Sinus Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this randomized trial is to assess the utility of Pupillary Dilatation Reflex (PRD) for monitoring pain perception intraoperatively and its influence on intraoperative blood loss, quality of surgical field using Boezaart Bleeding Scale (BBS) in patients undergoing functional sinus surgery (FESS) under total intravenous anaesthesia using propofol or volatile anaesthesia using sevoflurane or desflurane

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Remifentanil

Trials testing the same drug.

Other Medical University of Silesia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03417206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing